CLPT: The Pendulum Swung Too Far

A Mere Pit Stop

Many astute investors know markets overshoot — that's not a novel observation. Occasionally, however, the overshoot is precise enough, and the underlying business durable enough, that the entry point becomes obvious in retrospect. I think that's where Clearpoint Neuro is today. I have written (and pounded the table) about ClearPoint Neuro previously, and on Friday the business traded at the lowest valuation it has seen since the bottom of the biotech trough.